Phase 3 Trial Evaluating Magrolimab Combo for MDS Discontinued for Futility
source: shutterstock.com

Phase 3 Trial Evaluating Magrolimab Combo for MDS Discontinued for Futility

In 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to magrolimab for the treatment of newly diagnosed myelodysplastic syndromes (MDS). This designation is designed to expedite…

Continue Reading Phase 3 Trial Evaluating Magrolimab Combo for MDS Discontinued for Futility